SpringerProtocols: Abstract: Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia

Antithrombotic Drugs for the Treatment of Heparin-Induced Thrombocytopenia

By: Walter P. Jeske², Jeanine M. Walenga²

Abstract

Full Text

Download PDF (170K)

Heparin remains the anticoagulant of choice in the therapy of thromboembolic events. Heparin is effective in the prevention and treatment of venous thromboembolism (VTE), as a surgical anticoagulant, and in interventional cardiology (1). Heparin is also used in the treatment of unstable angina and acute myocardial infarction (AMI), and in some patients with disseminated intravascular coagulation. Although the clinical effects of heparin are meritorious, side effects do occur. Bleeding is the primary undesirable effect of heparin. Heparin-induced thrombocytopenia (HIT), the most frequent of drug-induced allergies, necessitates the use of alternative agents to treat or prevent thrombus formation.

Affiliation(s): (2) Departments of Thoracic-Cardiovascular Surgery and Pathology, Cardiovascular Institute, Loyola University Medical Center, Maywood, IL

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 61-82 | DOI: 10.1385/1-59259-658-4:61

Subject: Molecular Medicine

References

Download References

1.	Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., et al. (2001) Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 119, 64S–94S.

2.	Lewis, B. E., Walenga, J. M., and Wallis, D. E. (1997) Anticoagulation with Novastan® (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin. Thromb. Hemost. 23(2), 197.

3.	Messmore, H. L., Upadhyay, G., Farid, S., Parachuri, R., Wehrmacher, W., and Godwin, J. (1993) Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery, in New Anticoagulants for the Cardiovascular Patient (Pifarré, R., ed.), Philadelphia, Hanley & Belfus, Inc., p. 83.

4.	Walenga, J. M., Lewis, B. E., Hoppensteadt, D. A., Fareed, J., and Bakhos, M. (1997) Management of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Clin. Appl. Thromb. Hemost. 3(Suppl. 1), S53–S63.

5.	Warkentin, T. E. and Kelton, J. G (2001) Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344(17), 1286–1292.

6.	Warkentin, T. E. and Kelton, J. G. (2001) Delayed onset of heparin-induced thrombocytopenia. Ann. Intern. Med. 135(7), 502–506.

7.	Walenga, J. M., Jeske, W. P., Wood, J. J., Ahmad, S., Lewis, B. E., and Bakhos, M. (1999) Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin. Hematol. 36(Suppl. 1), 22–28.

8.	Walenga, J. M., Jeske, W. P., Fasanella, A. R., Wood, J. J., Ahmad, S., and Bakhos, M. (1999) Laboratory diagnosis of heparin-induced thrombocytopenia. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S21–S27.

9.	Warkentin, T. E., Hayward, C. P., Boshkov, C. K., et al. (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin induced thrombocytopenia. Blood 84, 3691.

10.	Warkentin, T. E. and Kelton, J. G. (1996) A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101, 502–507. The authors document the high occurrence of venous thrombosis in patients with HIT and the high 30-d risk of developing thrombosis in patients initially recognized with isolated thrombocytopenia.

11.	Greinacher, A., Eckhardt, T., Mussman, J., et al. (1993) Pregnancy complicated by heparin associated thrombocytopenia management by a prospective in vitro selected heparinoid (ORG 10172). Thromb. Res. 71, 123.

12.	Stewart, M. W., Etches, W. S., Boshkov, L. K., et al. (1995) Heparin-induced thrombocytopenia: an improved method of detection based on lumiaggregometry. Br. J. Haematol. 91, 173.

13.	Wallis, D. E., Workman, D. L., Lewis, B. E., Steen, L., Pifarré, R., and Moran, J. F. (1999) Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am. J. Med. 106(6), 629–635. Retrospective study of 113 patients with HIT demonstrating that early cessation of heparin did not reduce the morbidity associated with HIT.

14.	Moberg, P., Geary, V., and Sheikh, M. (1990) Heparin-induced thrombocytopenia: a possible complication of heparin-coated pulmonary artery catheters. J. Cardiothorac. Anesth. 4, 266.

15.	Weismann, R. E. and Tobin, R. W. (1958) Arterial embolism occurring with systemic heparin therapy. AMA Arch. Surg. 76, 219.

16.	Amiral, J., Bridey, F., Dreyfus, M., et al. (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemostasis 68(1), 95.

17.	Aster, R. H. (1995) Heparin-induced thrombocytopenia and thrombosis. N. Engl. J. Med. 332, 1374.

18.	Brandt, J. T., Isenhart, C. E., Osborne, J. M., et al. (1995) On the role of platelet Fc(RIIA phenotype in heparin induced thrombocytopenia. Thromb. Haemostasis 74, 1564.

19.	Cines, D. B., Tomaski, A., and Tannenbaum, S. (1987) Immune endothelial-cell injury in heparin associated thrombocytopenia. N. Engl. J. Med. 316, 581.

20.	Greinacher, A., Michels, I., Liebenhoff, U., et al. (1993) Heparin-associated thrombocytopenia: Immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br. J. Haematol. 84, 711.

21.	Greinacher, A., Pötzsch, B., Amiral, J., et al. (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF-4 heparin complex as the major antigen. Thromb. Haemostasis 71, 247.

22.	Kelton, J. G., Smith, J. W., Warkentin, T. E., et al. (1994) Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83, 3232.

23.	Visentin, G. P., Ford, S. E., Scott, J. P., et al. (1995) Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93, 81.

24.	Jeske, W. P., Walenga, J. M., Szatkowski, E., Ero, M., Herbert, J. M., Haas, S., et al. (1997) Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb. Res. 88, 271–281.

25.	Walenga, J. M., Michal, K., Hoppensteadt, D., Wood, J. J., Bick, R. L., and Robinson, J. A. (1999) Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S76–S84.

26.	Herbert, J. M., Savi, P., Jeske, W. P., and Walenga, J. M. (1998) Effect of SR121566A, a potent GPIIb/IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb. Haemostasis 80, 326–331.

27.	Chong, B. H. (1995) Heparin-induced thrombocytopenia (Review). Br. J. Haematol. 89, 431–439.

28.	Walenga, J. M., Koza, M. J., Lewis, B. E., and Pifarré, R. (1996) Relative heparin induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin. Appl. Thromb. Hemost. 2(Suppl. 1), S21.

29.	Newman, P. M. and Chong, B. H. (2000) Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 96, 182–187.

30.	Pouplard, C., Lochmann, S., Renard, B., Herault, O., Colombat, P., Amiral, J., and Gruel, Y. (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97(10), 3300–3302.

31.	Hughes, M., Hayward, C. P. M., Warkentin, T E., Horsewood, P., Chorneyko, K. A., and Keltonm, J. G. (2000) Morphological analysis of microparticle generation in heparin-induced thrombocytopenia. Blood 96, 188–194.

32.	Jeske, W. P., Schlenker, R., Bakhos, M., and Walenga, J. M. (2000) Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann. Hematol. 79(Suppl. I), A46.

33.	Jeske, W. P., Vasaiwala, S., Schlenker, R., Wallis, E., and Walenga, J. M. (2000) Leukocyte activation in heparin-induced thrombocytopenia. Blood 96(11), 29b.

34.	Blank, M., Shoenfeld, Y., Tavor, S., Praprotnik, S., Boffa, M. C., Weksler, B. B., et al. (2002) Anti-PF4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int. Immunol. 14(2), 121–129.

35.	Baugh, M. J., Prechel, M., Hoppensteadt, D., Wallis, E. R., Bick, R. L., and Walenga, J. M. (2000) The role of CD40-ligand and anti-annexin V antibodies in the pathophysiology of the APS and HIT. Blood 96(11), 272a.

36.	Ahmad, S., Walenga, J. M., Jeske, W. P., Cella, G., and Fareed, J. (1999) Functional heterogeneity of anti-heparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Clin. Appl. Thromb. Hemost. 5(Suppl. 1), S32–S37.

37.	Ahmad, S., Walenga, J. M., Jeske, W. P., Hoppensteadt, D. A., Khan, E., Cella, G., et al. (1999) Lack of thrombocytopenic responses after low molecular weight heparin usage is due to the generation of non-functional anti-heparin-PF4 antibodies. Blood 94(10), 624a.

38.	Mattioli, A. V., Bonetti, L., Sternieri, S., and Mattioli, G. (2000) Heparin-induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1 year follow-up. Ital. Heart. J. 1(1), 39–42. Study shows an increase in thrombotic events at 1 yr follow-up in patients with anti-heparin/PF4 antibodies compared to those without antibodies, despite no evidence of thrombocytopenia.

39.	Amiral, J., Pouplard, C., Vissac, A. M., Walenga, J. M., Jeske, W., and Gruel, Y. (2000) Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: Biological characteristics and effects on platelet activation. Br. J. Haematol. 109(2), 336–341.

40.	Pouplard, C. A., Amiral, J., Vissac, A. M., Walenga, J. M., Jeske, W. P., and Gruel, Y. J. (1999) Affinity purification of different heparin-dependent antibodies to PF4 developed in HIT. Biological characteristics and effects on platelet activation. Blood 94(10), 16a.

41.	Carlsson, L. E., Santoso, S., Baurichter, G., Kroll, H., Papenberg, S., Eichler, P., et al. (1998) Heparin-induced thrombocytopenia: new insights into the impact of the Fc(RIIa-R-H131 polymorphism. Blood 92(5), 1526–1531.

42.	Kappa, J. R., Fisher, C. A., Berkowitz, H. D., Cottrell, E. D., and Addonizio, V. P. (1987) Heparin-induced platelet activation in sixteen surgical patients: Diagnosis and management. J. Thorac. Cardiovasc. Surg. 5, 101.

43.	Warkentin, T. E., Levine, M. N., Hirsh, J., et al. (1995) Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330.

44.	Ahmad, S., Walenga, J. M., Jeske, W. P., Hoppensteadt, D. A., and Bakhos, M. (2001) Molecular weight and charge dependence of heparin on the pathogenic responses of anti-heparin platelet factor 4 antibodies. Thromb. Haemostasis (July Suppl.), CD-ROM, P2729.

45.	Greinacher, A., Feigl, M., and Mueller-Eckhardt, C. (1994) Cross-reactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb. Haemostasis 72(4), 644.

46.	Altés, A., Rodrigo, M., Gari, M., et al. (1995) Heparin-induced thrombocytopenia and heart operation: management with tedelparin. Ann. Thorac. Surg. 59, 508.

47.	Leroy, J., LeClerc, M. H., Delahousse, B., et al. (1985) Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin. Thromb. Hemost. 11(3), 326.

48.	Robitaille, D., Leclerc, J. R., Laberge, R., et al. (1992) Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J. Thome. Cardiovasc. Surg. 103(3), 597.

49.	Roussi, J. H., Houbouyan, L. L., and Goguel, A. F. (1984) Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet (May 26), 1183.

50.	Eichinger, S., Kyrle, R. A., Brenner, B., et al. (1991) Thrombocytopenia associated with low-molecular-weight heparin. Lancet 337, 1425.

51.	Gouault-Heilmann, M., Payen, D., Contant, G., et al. (1985) Thrombocytopenia related to synthetic heparin analogue therapy. Thromb. Haemostasis 54(2), 557.

52.	Wallis, D. E., Quintos, R., Whermacher, W., and Messmore, H. (1999) Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia. Chest 116, 1333–1338.

53.	Walenga, J. M., Fasanella, A. R., Iqbal, O., Hoppensteadt, D. A., Ahmad, S., Wallis, D. E., et al. (1999) Coagulation laboratory testing in patients treated with argatroban. Semin. Thromb. Hemost. 25(Suppl. 1), 61–66.

54.	Sheth, S. B., DiCicco, R. A., Hursting, M. J., Montague, T., and Jorkasky, D. K. (2001) Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb. Haemostasis 85, 435–440.

55.	Hursting, M. J., Zehnder, J. L., Joffrion, J. L., Becker, J. C., Knappenberger, G. D., and Schwarz, R. R (1999) The interventional normalization ratio during concurrent warfarin and argatroban anticoagulation differential contributions of each agent and effects of the choice of the thromboplastin used. Clin. Chem. 45(13), 409–412.

56.	Lewis, B. E., Leya, F. S., Wallis, D., and Grassman, E. (1994) Failure of ancrod in the treatment of heparin-induced arterial thrombosis. Can. J. Cardiol. 10(5), 559.

57.	Chamberlin, J. R., Lewis, B., Leya, F., et al. (1995) Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can. J. Cardiol. 11(6), 511.

57a.	Reid, T., Alving, B. M. (1994) Hrulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am. J. Hematol. 45, 352–353.

57b.	Campbell, K. R., Mahaffey, K. W., Lewis, B. E., Weitz, J. I., Berkowitz, S. D., Ohman, E. M., et al. (2000) Bivalirudin in patients with heparin-induced thrombocytopenia underoing percutaneous coronary intervention. J. Invas. Cardiol. 12(Suppl F), 14F-9.

58.	Walenga, J. M., Lewis, B. E., Jeske, W. R., Leya, F., Wallis, D. E., Bakhos, M., et al. (1999) Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 19, 128–133. Describes the use of the combination of a GP Ilb/IIIa inhibitor and a direct thrombin inhibitor for the treatment of acute thrombosis in patients with HIT.

59.	Lewis, B. E., Wallis, D. E., Berkowitz, S. D., Matthai, W. H., Fareed, J., Walenga, J. M., et al., for the ARG-911 Study Investigators (2001) Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103(14), 1838–1843. Argatroban is shown to reduce all-cause death, all-cause amputation, and new thrombosis in patients with HIT.

60.	Lewis, B. E., Ferguson, J. J., Grassman, E. D., Fareed, J., Walenga, J. M., Joffrion, J. L., et al. (1996) Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J. Invas. Cardiol. 8(9), 410–417.

61.	Lewis, B. E., Iqbal, O., Hoppensteadt, D., Ahsan, A., Ahmad, S., Messmore, H. L., et al. (1997) Clinical pharmacokinetic and pharmacodynamic studies on argatroban to optimize the anticoagulant dosage in interventional cardiovascular procedures [abstract]. Thromb. Haemostasis (Suppl.), 492.

62.	Lewis, B. E., Rangel, Y., and Fareed, J. (1998) The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: A case report. Angiology 49(1), 61–67.

63.	Lewis, B. E., Cohen, M., Moses, J., Matthai, W., for the ARG-216/310/311 investigators (2000) Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia [abstract]. Am. J. Cardiol. 86(Suppl. 8A), 141.

63a.	Jang, I. K., Lewis, B. E., Matthai, W. H., and Kleiman, N. S. (2003) Combination of a direct thrombin inhibitor, argatroban, and glycoprotein IIb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J. Am. Coll. Cardiol. 41(6 Suppl A), 68A.

64.	Greinacher, A., Volpel, H., Janssens, U., Hach-Wunderle, V., Kemkes-Matthes, B., Eichler, P., et al., for the HIT Investigators Group (1999) Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation 99, 73–80. Clinical benefit of r-hirudin treatment in HIT patients is described.

65.	Greinacher, A., Janssens, U., Berg, G., Bock, M., Kwasny, H., Kemkes-Matthes, B., et al., for the HAT investigators (1999) Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100(6), 587–593.

66.	Pötzsch, B. and Klovekorn, W. P. (2000) Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N. Engl. J. Med. 343, 515.

67.	Koster, A., Loebe, M., Mertzluftt, F., Kuppe, H., and Hetzer, R. (2000) Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant. Ann. Thorac. Surg. 70(6), 2160–2161.

68.	Kappa, J. R., Fisher, C. A., and Todd, B. (1990) Intraoperative management of patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 49, 714.

69.	Fabrizio, M. C. (2001) Use of the ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J. Extracorp. Tech. 33(2), 117–125.

70.	Riess, F. C., Kormann, J., and Poetzsch, B. (2000) Recombinant hirudin as anticoagulant during cardiopulmonary bypass. Anesthesiology 93(6), 1551–1552.

71.	Shah, A. C.,, Genoni, M., Niederhauser, U., Maloigne, M., and Turina, M. (2000) R-hirudin (lepirudin, refludan) as an alternative anticoagulant in heparin-induced thrombocytopenia during cardiopulmonary bypass connection (German). Schweizerische Medizinische Wocenschrift. Journal Suisse de Medicine 130(23), 896–899.

72.	Rubens, F. D., Sabloff, M., Wells, P. S., and Bourke, M. (2000) Use of recombinant hirudin in pulmonary thromboendarterectomy. Ann. Thorac. Surg. 69(6), 1942–1943.

73.	Koster, A., Loebe, M., Hansen, R., Bauer, M., Mertzlufft, F., Kuppe, H., et al. (2000) A quick assay for monitoring hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: adaptation of the ecarin clotting time to the ACT II device. J. Thorac. Cardiovasc. Surg. 119(6), 1278–1283.

74.	Longrois, D., de Maistre, E., Bischoff, N., Dopff, C., Meistelman, C., Angioi, M., et al. (2000) Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Can. J. Anaesthesiol. 47(3), 255–260.

75.	Latham, P., Revelis, A. F., Joshi, G. R, DiMaio, J. M., and Jessen, M. E. (2000) Use of recombinant hirudin in patients with heparin-induced thrombocytopenia with thrombosis requiring cardiopulmonary bypass. Anesthesiology 92(1), 263–266.

76.	Koster, A., Pasic, M., Bauer, M., Kuppe, H., and Hetzer, R. (2000) Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann. Thorac. Surg. 69(1), 37–41.

77.	Koster, A., Kuppe, H., Hetzer, R., Sodian, R., Crystal, G. J., and Mertzlufft, F. (1998) Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin. Anesthesiology 89(3), 777–780.

77a.	Lewis, B. E., Grassman, E. D., Wrona, L., Rangel, Y. (1997) Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coag. Fibrinol. 8(1), 54–58.

77b.	Lewis, B. E., Rangel, Y., Fareed, J. (1998) The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 49, 61–67.

77c.	Matsuo, T., Chikahira, Y., Yamada, T., Nakao, K., Ueshima, S., Matsuo, O., (1998) Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin-induced thrombocytopenia during hemodialysis. Thromb. Res. 52, 165–171.

77d.	Koide, M., Yamamoto, S., Matsuo, M., Suzuki, S., Arima, N., Matsuo, T., (1995) Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol. Dial. Transplant 10, 2137–2140.

77e.	Steuer, S., Boogen, C., Plum, J., Deppe, C., Reinauer, H., Grabensee, B. (1999) Anticoagulation with r-hirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Nephrol. Dial. Transplant 14, 45–47.

77f.	Schneider, T., Heuer, B., Deller, A., Boesken, W. H. (2000) Continuous hemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin-induced thrombocytopenia (HIT II). Wein. Klin. Wochenschr. 112, 552–555.

77g.	Van Wyck, V., Badenhorst, P. N., Luus, H. G., Kotze, H. F. (1995) A comparison betweenthe use of recombinant hirudin and heparin during hemodialysis. Kidney Int. 48, 1338–1343.

77h.	Manfredi, J. A., Wall, R. P., Sane, D. C., Braden, G. A. (2001) Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports. Cath. Cardiovasc. Intervent. 52(4), 468–472.

77i.	Pinto, D. S., Sperling, R. T., Tu, T. M., Cohen, D. J., Carrozza, J. P. (2003) Combination platelet glycoprotein Ilb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cath. Cardiovasc. Intervent. 58(1), 65–68.

78.	Chong, B. H., Ismail, F., Cade, J., et al. (1989) Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 73(6), 1592.

79.	Haas, S., Walenga, J. M., Jeske, W. P., and Fareed, J. (1999) Heparin-induced thrombocytopenia: Clinical considerations of alternative anticoagulation with various glycosaminoglycans and thrombin inhibitors. Clin. Appl. Thrombosis/Hemostasis 5(Suppl. 1), 52–59.

80.	Magnani, H. N. (1993) Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb. Haemostasis 70(4), 554.

81.	Ortel, T. L., Gocherman, J. P., Califf, R. M., et al. (1992) Parenteral anticoagulation with the heparinoid Lomoparan (ORG 10172) in patients with heparin-induced thrombocytopenia and thrombosis. Thromb. Haemostasis 67(3), 292.

82.	Cohen, J. I., Cooper, M. R., and Greenberg, C. S. (1985) Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch. Intern. Med. 135, 1725–1726.

83.	Fiessinger, J. N., Aiach, M., Roncato, M., et al. (1984) Critical ischemia during heparin-induced thrombocytopenia. Treatment by intra-arterial streptokinase. Thromb. Res. 33, 235.

84.	Rao, R. C., Lewis, B. E., and Johnson, S. A. (1995) Thrombolytic experience for treatment of thrombosis in patients with post-operative heparin-induced thrombocytopenia. Blood 86(10)(Suppl. 1), 551a.

85.	Haas, S., Walenga, J. M., Jeske, W. P., and Fareed, J. (1999) Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin. Thromb. Hemost. 25(Suppl. 1), 67–76.

Comments (Loading...)

Post comment/View all comments